Dyne Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: DYN · Form: 8-K · Filed: May 24, 2024 · CIK: 1818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, INC. (DYN) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Dyne Therapeutics filed an 8-K for shareholder vote matters on 5/22.
AI Summary
Dyne Therapeutics, Inc. filed an 8-K on May 24, 2024, reporting on matters submitted to a vote of its security holders on May 22, 2024. The filing details the company's corporate information, including its principal executive offices in Waltham, Massachusetts.
Why It Matters
This filing provides an official record of important corporate actions and decisions made by Dyne Therapeutics' shareholders, which can influence the company's strategic direction and governance.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain new financial or operational information that would immediately impact the company's risk profile.
Key Players & Entities
- Dyne Therapeutics, Inc. (company) — Registrant
- May 22, 2024 (date) — Date of earliest event reported
- May 24, 2024 (date) — Date of report
- Waltham, Massachusetts (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Dyne Therapeutics' security holders on May 22, 2024?
The filing states that matters were submitted to a vote of security holders on May 22, 2024, but does not specify the exact nature of these matters within the provided text.
What is the Commission File Number for Dyne Therapeutics, Inc.?
The Commission File Number for Dyne Therapeutics, Inc. is 001-39509.
Where are Dyne Therapeutics, Inc.'s principal executive offices located?
Dyne Therapeutics, Inc.'s principal executive offices are located at 1560 Trapelo Road, Waltham, Massachusetts, 02451.
What is the IRS Employer Identification Number for Dyne Therapeutics, Inc.?
The IRS Employer Identification Number for Dyne Therapeutics, Inc. is 36-4883909.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-05-24 17:00:18
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share DYN Nasdaq Glob
Filing Documents
- dyn-20240522.htm (8-K) — 56KB
- 0000950170-24-064700.txt ( ) — 175KB
- dyn-20240522.xsd (EX-101.SCH) — 30KB
- dyn-20240522_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. Dyne Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders on May 22, 2024. The following is a summary of the matters voted on at that meeting. a) The stockholders of the Company elected Carlo Incerti, M.D., Catherine Stehman-Breen, M.D. and John G. Cox as Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified. The results of the stockholders' vote with respect to such matter were as follows: Name For Withheld Broker Non-Votes Carlo Incerti, M.D. 61,028,245 8,752,856 5,235,919 Catherine Stehman-Breen, M.D. 55,026,485 14,325,362 5,665,173 John G. Cox 69,763,860 32,767 5,220,393 b) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders' vote with respect to such matter were as follows: For Against Abstain 74,962,217 12,377 42,426
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DYNE THERAPEUTICS, INC. Date: May 24, 2024 By: /s/ John G. Cox Name: John G. Cox Title: President and Chief Executive Officer